[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341119-105":59,"doc-detail-341119-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","immune-checkpoint-inhibitors-in-the-treatment-of-hepatocellular-carcinoma-review","Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma - Review","","Hepatocellular carcinoma (HCC) remains a major global public health challenge, driven by tumor–immune microenvironment interactions that promote immune evasion, progression, and metastasis. This review describes how immune checkpoint pathways regulate anticancer immunity and summarizes clinical-trial evidence for immune checkpoint inhibitors (ICIs) used as monotherapy or combined with anti-angiogenic agents and tyrosine kinase inhibitors. It also outlines practical challenges and considerations for administering ICIs in HCC.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immune-checkpoint-inhibitors-in-the-treatment-of-hepatocellular-carcinoma-review/341119/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immune-checkpoint-inhibitors-in-the-treatment-of-hepatocellular-carcinoma-review/341119.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why does the immune microenvironment matter in hepatocellular carcinoma (HCC)?","Question",{"text":113,"@type":114},"The tumor microenvironment contains immunosuppressive cells and signals that facilitate immune evasion and metastasis. This immune context strongly influences tumor progression and resistance to therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do immune checkpoint inhibitors (ICIs) improve outcomes in HCC?",{"text":118,"@type":114},"Clinical trials show that ICIs, especially when combined with anti-angiogenic agents and tyrosine kinase inhibitors, can prolong survival and provide durable cancer control in a subset of patients.",{"name":120,"@type":111,"acceptedAnswer":121},"What types of ICIs and treatment settings are covered in the review?",{"text":122,"@type":114},"The review summarizes findings from clinical trials in which ICIs are used as monotherapies or combined with other agents for HCC treatment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341119,1790150805,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Review  \nPUBLISHED 04 April 2024  \nDOI 10.3389/fimmu.2024.1379622  \nOPEN ACCESS  \nEDITED BY  \nSimona Kranjc Brezar,  \nInstitute of Oncology Ljubljana, Slovenia  \nREVIEWED BY Jozsef Dudas,  \nInnsbruck Medical University, Austria Jiqiao Zhu,  \nCapital Medical University, China  \n*CORRESPONDENCE Gülderen Yanıkkaya Demirel  \n [gulderen.ydemirel@yeditepe.edu.tr](gulderen.ydemirel@yeditepe.edu.tr)[ ](gulderen.ydemirel@yeditepe.edu.tr)Zeynep Akbulut  \n [zeynep.akbulut@maltepe.edu.tr](zeynep.akbulut@maltepe.edu.tr)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 31 January 2024  \nACCEPTED 18 March 2024  \nPUBLISHED 04 April 2024  \nCITATION  \nAkbulut Z, Aru B, Aydın F and Yanıkkaya Demirel G (2024) Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.  \nFront. Immunol. 15:1379622 .  \ndoi: 10.3389/fimmu.2024.1379622  \nCOPYRIGHT  \n© 2024 Akbulut, Aru, Aydın and Yanıkkaya Demirel. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImmune checkpoint inhibitors in the treatment of hepatocellular carcinoma  \nZeynep Akbulut 1,2*†, Baak Aru 3†, Furkan Ayd ın3 and Gülderen Yanıkkaya Demirel 3*  \n1Cancer and Stem Cell Research Center, Maltepe University, Istanbul, Türkiye, 2 Department of Medical Biology and Genetics, Faculty of Medicine, Maltepe University, Istanbul, Türkiye, 3 Department of Immunology, Faculty of Medicine, Yeditepe University, Istanbul, Türkiye  \nDespite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common form of liver cancer, remains a major public health problem worldwide. The immune microenvironment plays a critical role in regulating tumor progression and resistance to therapy, and in HCC, the tumor microenvironment (TME) is characterized by an abundance of immunosuppressive cells and signals that facilitate immune evasion and metastasis. Recently, anti-cancer immunotherapies, therapeutic interventions designed to modulate the immune system to recognize and eliminate cancer, have become an important cornerstone of cancer therapy. Immunotherapy has demonstrated the ability to improve survival and provide durable cancer control in certain groups of HCC patients, while reducing adverse side effects. These ﬁndings represent a signiﬁcant step toward improving cancer treatment outcomes. As demonstrated in clinical trials, the administration of immune checkpoint inhibitors (ICIs), particularly in combination with anti-angiogenic agents and tyrosine kinase inhibitors, has prolonged survival in a subset of patients with HCC, providing an alternative for patients who progress on ﬁrst-line therapy. In this review, we aimed to provide an overview of HCC and the role of the immune system in its development, and to summarize the ﬁndings of clinical trials involving ICIs, either as monotherapies or in combination with other agents in the treatment of the disease. Challenges and considerations regarding the administration of ICIs in the treatment of HCC are also outlined.  \nKEYWORDS  \nhepatocellular carcinoma, immune checkpoint proteins, immune checkpoint inhibition, tumor microenvironment, anticancer immunity  \n1 Introduction  \nIn 2020, liver cancer emerged as a global health problem with 905,700 new cases, accounting for nearly 5% of all cancer diagnoses, and 830,200 deaths, consolidating its position as the third leading cause of cancer-related deaths worldwide, after lung and colorectal cancer. The mortality/incidence ratio, an indicator of the severity of the disease,  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nwas report","cbCaipfZps0pdzH9","https://ap.wps.com/l/cbCaipfZps0pdzH9","pdf",1998571,18,"English","# Introduction\n## Immune microenvironment and rationale for ICIs\n# Clinical trials and therapeutic combinations\n## ICI monotherapy and combination strategies\n# Challenges and considerations\n## Administration of ICIs in HCC","[{\"question\":\"Why does the immune microenvironment matter in hepatocellular carcinoma (HCC)?\",\"answer\":\"The tumor microenvironment contains immunosuppressive cells and signals that facilitate immune evasion and metastasis. This immune context strongly influences tumor progression and resistance to therapy.\"},{\"question\":\"How do immune checkpoint inhibitors (ICIs) improve outcomes in HCC?\",\"answer\":\"Clinical trials show that ICIs, especially when combined with anti-angiogenic agents and tyrosine kinase inhibitors, can prolong survival and provide durable cancer control in a subset of patients.\"},{\"question\":\"What types of ICIs and treatment settings are covered in the review?\",\"answer\":\"The review summarizes findings from clinical trials in which ICIs are used as monotherapies or combined with other agents for HCC treatment.\"}]","Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma - Review | PDF",1790040421,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e7029ccebd3f1a6b9c0c9178ce8e1fc.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c173477662f4d1c08918983cf40ecc83.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38a302bd250ad8e8713c80c9d5b74518.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0345c73809ffdf8da3bef59b5f960fb.webp",980,1385]